# Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

> **NCT04739202** · PHASE2 · UNKNOWN · sponsor: **Hospices Civils de Lyon** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Metastatic Gastric Cancer
- Metastatic Adenocarcinoma
- Advanced Gastric Carcinoma

## Interventions

- **DRUG:** Atezolizumab + Ipatasertib
- **DRUG:** Atezolizumab + Bevacizumab

## Key facts

- **NCT ID:** NCT04739202
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-19
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04739202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04739202, "Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04739202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*